Cargando…

E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition

Cyclins are central engines of cell cycle progression in conjunction with cyclin‐dependent kinases (CDKs). Among the different cyclins controlling cell cycle progression, cyclin F does not partner with a CDK, but instead forms via its F‐box domain an SCF (Skp1‐Cul1‐F‐box)‐type E3 ubiquitin ligase mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Burdova, Kamila, Yang, Hongbin, Faedda, Roberta, Hume, Samuel, Chauhan, Jagat, Ebner, Daniel, Kessler, Benedikt M, Vendrell, Iolanda, Drewry, David H, Wells, Carrow I, Hatch, Stephanie B, Dianov, Grigory L, Buffa, Francesca M, D'Angiolella, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792013/
https://www.ncbi.nlm.nih.gov/pubmed/31424118
http://dx.doi.org/10.15252/embj.2018101443
_version_ 1783459065415860224
author Burdova, Kamila
Yang, Hongbin
Faedda, Roberta
Hume, Samuel
Chauhan, Jagat
Ebner, Daniel
Kessler, Benedikt M
Vendrell, Iolanda
Drewry, David H
Wells, Carrow I
Hatch, Stephanie B
Dianov, Grigory L
Buffa, Francesca M
D'Angiolella, Vincenzo
author_facet Burdova, Kamila
Yang, Hongbin
Faedda, Roberta
Hume, Samuel
Chauhan, Jagat
Ebner, Daniel
Kessler, Benedikt M
Vendrell, Iolanda
Drewry, David H
Wells, Carrow I
Hatch, Stephanie B
Dianov, Grigory L
Buffa, Francesca M
D'Angiolella, Vincenzo
author_sort Burdova, Kamila
collection PubMed
description Cyclins are central engines of cell cycle progression in conjunction with cyclin‐dependent kinases (CDKs). Among the different cyclins controlling cell cycle progression, cyclin F does not partner with a CDK, but instead forms via its F‐box domain an SCF (Skp1‐Cul1‐F‐box)‐type E3 ubiquitin ligase module. Although various substrates of cyclin F have been identified, the vulnerabilities of cells lacking cyclin F are not known. Thus, we assessed viability of cells lacking cyclin F upon challenging them with more than 180 different kinase inhibitors. The screen revealed a striking synthetic lethality between Chk1 inhibition and cyclin F loss. Chk1 inhibition in cells lacking cyclin F leads to DNA replication catastrophe. Replication catastrophe depends on accumulation of the transcription factor E2F1 in cyclin F‐depleted cells. We find that SCF‐cyclin F controls E2F1 ubiquitylation and degradation during the G2/M phase of the cell cycle and upon challenging cells with Chk1 inhibitors. Thus, Cyclin F restricts E2F1 activity during the cell cycle and upon checkpoint inhibition to prevent DNA replication stress. Our findings pave the way for patient selection in the clinical use of checkpoint inhibitors.
format Online
Article
Text
id pubmed-6792013
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67920132019-10-21 E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition Burdova, Kamila Yang, Hongbin Faedda, Roberta Hume, Samuel Chauhan, Jagat Ebner, Daniel Kessler, Benedikt M Vendrell, Iolanda Drewry, David H Wells, Carrow I Hatch, Stephanie B Dianov, Grigory L Buffa, Francesca M D'Angiolella, Vincenzo EMBO J Articles Cyclins are central engines of cell cycle progression in conjunction with cyclin‐dependent kinases (CDKs). Among the different cyclins controlling cell cycle progression, cyclin F does not partner with a CDK, but instead forms via its F‐box domain an SCF (Skp1‐Cul1‐F‐box)‐type E3 ubiquitin ligase module. Although various substrates of cyclin F have been identified, the vulnerabilities of cells lacking cyclin F are not known. Thus, we assessed viability of cells lacking cyclin F upon challenging them with more than 180 different kinase inhibitors. The screen revealed a striking synthetic lethality between Chk1 inhibition and cyclin F loss. Chk1 inhibition in cells lacking cyclin F leads to DNA replication catastrophe. Replication catastrophe depends on accumulation of the transcription factor E2F1 in cyclin F‐depleted cells. We find that SCF‐cyclin F controls E2F1 ubiquitylation and degradation during the G2/M phase of the cell cycle and upon challenging cells with Chk1 inhibitors. Thus, Cyclin F restricts E2F1 activity during the cell cycle and upon checkpoint inhibition to prevent DNA replication stress. Our findings pave the way for patient selection in the clinical use of checkpoint inhibitors. John Wiley and Sons Inc. 2019-08-19 2019-10-15 /pmc/articles/PMC6792013/ /pubmed/31424118 http://dx.doi.org/10.15252/embj.2018101443 Text en © 2019 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles
Burdova, Kamila
Yang, Hongbin
Faedda, Roberta
Hume, Samuel
Chauhan, Jagat
Ebner, Daniel
Kessler, Benedikt M
Vendrell, Iolanda
Drewry, David H
Wells, Carrow I
Hatch, Stephanie B
Dianov, Grigory L
Buffa, Francesca M
D'Angiolella, Vincenzo
E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition
title E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition
title_full E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition
title_fullStr E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition
title_full_unstemmed E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition
title_short E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition
title_sort e2f1 proteolysis via scf‐cyclin f underlies synthetic lethality between cyclin f loss and chk1 inhibition
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792013/
https://www.ncbi.nlm.nih.gov/pubmed/31424118
http://dx.doi.org/10.15252/embj.2018101443
work_keys_str_mv AT burdovakamila e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition
AT yanghongbin e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition
AT faeddaroberta e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition
AT humesamuel e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition
AT chauhanjagat e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition
AT ebnerdaniel e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition
AT kesslerbenediktm e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition
AT vendrelliolanda e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition
AT drewrydavidh e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition
AT wellscarrowi e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition
AT hatchstephanieb e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition
AT dianovgrigoryl e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition
AT buffafrancescam e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition
AT dangiolellavincenzo e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition